Akers Biosciences Signs Distribution Agreement for BreathScan OxiChek(TM)
June 27 2016 - 7:00AM
Marketwired
Akers Biosciences Signs Distribution Agreement for BreathScan
OxiChek(TM)
THOROFARE, NJ-(Marketwired - Jun 27, 2016) - Akers Biosciences,
Inc. (NASDAQ: AKER) (AIM: AKR) (the "Company" or "Akers Bio"), a
developer of rapid health information technologies, has signed its
first distribution agreement for BreathScan OxiChek ("OxiChek")
with Aero-Med, a division of Cardinal Health, a Fortune 500 health
care services organization.
Developed by Akers Bio as part of the Akers Wellness line,
OxiChek is the first disposable breath test to rapidly determine
levels of oxidative stress in the body by measuring the levels of
certain abundant free radicals. Frequent use of OxiChek may help
health practitioners to monitor and adjust their clients' regimen
of nutritional supplementation in order to manage oxidative stress
- an indicator of the overall health and wellbeing of a person.
OxiChek works with BreathScan Lync, the new Bluetooth-enabled
reading device from Akers Wellness, to enable users to monitor
oxidative stress via a mobile device.
Aero-Med is targeting the large specific markets in the United
States of anti-aging, functional and integrative health and
wellness treatment practitioners and has already placed orders for
OxiChek. OxiChek will be initially represented by an Aero-Med sales
team focusing on the six New England states both through direct
sales and, in due course, through an e-commerce platform under
development.
Akers Bio intends to appoint further partners for OxiChek with
distribution capabilities within other target markets for OxiChek
including chiropractors and multi-level marketing
organizations.
"The US health practitioner market is the most diverse in the
world," said John J. Gormally, CEO of Akers Bio. "OxiChek targets
many of these different potential user bases so we needed a
distributor with the broadest reach and I can think of no
organization better suited than Aero-Med, which has extensive
access to our target markets. I have worked with Aero-Med in the
past and have been highly impressed with their distribution
capabilities," continued Mr. Gormally.
Dan DelMastro, CEO of Aero-Med, added, "Aero-Med recognizes the
enormous market potential for products within the health and
wellness sector so we are delighted to be incorporating OxiChek
into our sales offering. Having personally observed the positive
customer reaction to OxiChek at conventions in recent months, I am
optimistic that there is strong potential for this product."
About Akers Biosciences, Inc.
Akers Biosciences develops, manufactures, and supplies rapid
screening and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target," "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:Akers Biosciences, Inc.Raymond F. Akers,
Jr., PhDCo-founder and Chief Scientific DirectorTel. +1 856 848
8698Taglich Brothers, Inc. (Investor Relations)Chris SchreiberTel.
+1 917 445 6207Email: cs@taglichbrothers.comVigo Communications
(Public Relations)Ben Simons / Fiona HensonTel. +44 (0)20 7830
9700Email: akers@vigocomms.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jul 2023 to Jul 2024